STRO
HEALTHCARESutro Biopharma
AI Insight
What's Moving STRO Today?
No stock-specific AI insight has been generated for STRO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.74$43.85
$30.03
Fundamentals
Market Cap$484M
P/E Ratio—
EPS$-16.35
Dividend Yield—
Dividend / Share—
ROE-1,810.0%
Profit Margin-154.2%
Debt / Equity—
Trading
Volume378K
Avg Volume (10D)—
Shares Outstanding16.6M
STRO News
21 articles- Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 MillionMotley Fool·May 31, 2026
- Barclays initiates oncology-focused biotechs with positive outlookYahoo Finance·May 28, 2026
- News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsYahoo Finance·May 28, 2026
- US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsYahoo Finance·May 17, 2026
- Sutro Biopharma (STRO) affiliates disclose 1.06M shares; ownership detailsStock Titan·May 15, 2026
- Sutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 14, 2026
- MannKind (MNKD) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 6, 2026
- Ocugen (OCGN) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Citizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramYahoo Finance·May 1, 2026
- Meta downgraded, Qualcomm upgraded: Wall Street's top analyst callsYahoo Finance·Apr 30, 2026
- Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowYahoo Finance·Apr 29, 2026
- Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026GlobeNewswire Inc.·Apr 19, 2026
- Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?Yahoo Finance·Apr 8, 2026
- Arm downgraded, Arista Networks upgraded: Wall Street's top analyst callsYahoo Finance·Apr 7, 2026
- Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains?Yahoo Finance·Apr 1, 2026
- Sutro Biopharma Reports Full Year 2025 Financial Results and Business HighlightsYahoo Finance·Mar 23, 2026
- Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 3, 2026
- Sutro Biopharma to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Sutro Biopharma Announces Participation at the 16th World ADC London SummitYahoo Finance·Feb 23, 2026
- Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?Yahoo Finance·Feb 11, 2026
- Sutro Biopharma Announces Pricing of $110.0 million Underwritten OfferingYahoo Finance·Feb 10, 2026
All 21 articles loaded
Price Data
Open$29.29
Previous Close$29.19
Day High$31.79
Day Low$29.29
52 Week High$43.85
52 Week Low$6.74
52-Week Range
$6.74$43.85
$30.03
Fundamentals
Market Cap$484M
P/E Ratio—
EPS$-16.35
Dividend Yield—
Dividend / Share—
ROE-1,810.0%
Profit Margin-154.2%
Debt / Equity—
Trading
Volume378K
Avg Volume (10D)—
Shares Outstanding16.6M
About Sutro Biopharma
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—